bellini, a phase iii study of venetoclax or placebo in combination with bortezomib and dex in rrmm
Published 4 years ago • 253 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
42:14
family genetics and a c3 variant
-
1:00:03
what does ai mean for medicine?
-
29:02
aduhelm (aducanumab) - alzheimer's drug - first choice neurology - jeffrey gelblum, md
-
1:03:03
eusomii/deepc webinar “radiology ai across the clinical value chain”
-
59:36
v3 in action
-
1:28
module 3 - complex cases - sample 2
-
2:02:00
interpretation of abg (part- 3) | medicine | genesis online university
-
3:15
developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
-
2:07
klinik's ai-driven total triage solution - how it works?
-
2:22
on-demand access to clinical and meta data using cdisc odm | medidata
-
2:45
imgn632 plus venetoclax and/or azacitidine for patients with cd123-positive aml
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
16:10
clinical case 1 - paulo abrão ferreira, md
-
21:44
initial therapy. two or three drugs? - alejandro afani, md
-
1:00
adrenalin (3) #cme #internal_medicine #usmle #pharmaceutical #doctor #medical #محاضرات_باطنة
-
2:11
sonnet 3 cochlea-implantat-audioprozessor | med-el
-
1:13
quest spectrum® 3.0